業績

2013年度 :: 学会発表 :: 国際学会 :: 業績

24th Asian Pacific Association for the Study of the Liver (APASL 2014)
2014. 3. Brisbane, Australia

<Poster>
Suda G, Yamamoto Y, Nagasaka A, Furuya K, Tsukuda Y, Tsunematsu S, Satou F, Terasita K, Horimoto K, Sh T, Nakai M, Natsuizka M, Chuma M, Sakamoto N.
Serum granulysin level is correlated with severity of telaprevir induced dermatological adverse reactions and could be a useful predictor.
Terashita K, Chuma M, Hatanaka K, Hatanaka Y, Yokoo H, Ohmura T, Nagasaka A, Ogawa K, Toyoda H, Kumada T, Suda G, Natsuizaka M, Kamiyama T, Taketomi A, Sakamoto N.
ZEB1 expression is a significant prognostic marker in intrahepatic cholangiocarcinoma.
Terashita K, Chuma M, Yamamamoto Y, Sho T, Horimoto H, Tsukada Y, Tsunematsu S, Nakanishi M, Sakamoto N.
Comparison of the efficacy of sorafenib and hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma.
Tsukuda Y, Suda G, Tsunematsu S, Satou F, Terasita K, Horimoto K, Sho T, Nakai M, Natsuizka M, Chuma M, Sakamoto N.
Anti-adipogenic and anti-viral effect of L-Carnitine on hepatitis C virus infection.

2014 International Forum on Ultrasound Applications (IFUA)
2014.3. Kachsiung, Taiwan

<Poster>
Sato T.
Hemodynamics and diagnosis of gastric varices secondary to splenic vein occlusion.

2014 Gastrointestinal Cancers Symposium (ASCO-GI 2014)
2014.1. San Francisco, USA

<Poster>
Doi A, Yuki S, Tsuji Y, Sasaki T, Fukushima H, Hatanaka K, Naruse H, Okuda H, Kusumi T, Fujikawa K, Takahashi Y, Saitoh S, Kajiura S, Hosokawa A, Watanabe Y, Yamamoto F, Kudo M, Akakura N, Sakata Y, Komatsu Y.
Analysis of Kohne's prognostic index in KRAS wild-type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.
Fujikawa K, Yuki S, Sasaki T, Takahashi Y, Iwanaga I, Uebayashi M, Saitoh S, Koike M, Nakamura M, Sato Y, Kudo M, Tateyama M, Kawamoto Y, Hisai H, Saito M, Onodera M, Takagi T, Sakata Y, Komatsu Y.
Comparison of adding cetuximab (Cmab) or panitumumab (Pmab) to irinotecan (IRI)-based chemotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSG0901 and 1002.
Gamoh M, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H, Imamura H, Matsuyama J, Shimokawa T, Sakai D, Kurokawa Y, Komatsu Y, Tsujinaka T, Ishioka C, Furukawa H.
Updated analysis of HERBIS-1: A phase ll study of trastuzumab (T-mab) in combination with tri-weekly S-1 plus CDDP in HER2-positive advanced gastric cancer.
Iwanaga C, Komatsu Y, Yuki S, Kobayashi Y, Sakamoto N, Uebayashi M, Okuda H, Kusumi T, Sogabe S, Miyagishima T, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Konno J, Yamamoto F, Iwai K, Onodera M, Oba K, Sakata Y.
Randomized controlled trial on the skin toxicity of panitumumab in third-line treatment of KRAS wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol with Panitumumab; J-STEPP).
Kato S, Fukushima H, Kato K, Yuki S, Harada K, Kobayashi Y, Sasaki T, Ehira N, Iwanaga I, Uebayashi M, Dazai M, Sogabe S, Miyagishima T, Kudo M, Hatanaka K, Naruse H, Tateyama M, Sakata Y, Komatsu Y.
Exploratory randomized trial to evaluate the effect of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV)/acute-onset diarrhea induced by IRIS/FOLFIRI: HGCSG0704.
Sasaki T, Komatsu Y, Yuki S, Harada K, Kobayashi Y, Fukushima H, Sakamoto N.
Evaluation of usefulness of Royal Marsden Hospital prognostic index in second-line chemotherapy of advanced gastric cancer.
Ueda A, Yuki S, Sasaki T, Kobayashi Y, Hosokawa A, Doi A, Tsuji Y, Okuda H, Kato T, Watanabe Y, Miyagishima T, Eto K, Ohta T, Takahata T, Ikeda S, Nakatsumi H, Iwai K, Kato K, Sakata Y, Komatsu Y.
Comparison of cetuximab (Cmab) with panitumumab (Pmab) monotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSG0901 and 1002.
Yuki S, Komatsu Y, Fukushima H, Sasaki T, Kobayashi Y, Harada K, Dazai M, Sogabe S, Miyagishima T, Ishiguro A, Takahata T, Sato A, Kudo M, Kato S, Kato K, Iwanaga I, Ehira N, Uebayashi M, Sakata Y.
Phase II trial of S-1 plus split cisplatin (SSP) in patients with advanced gastric cancer (HGCSG0702): Final report.
Yuki S, Komatsu Y, Fukushima H, Sasaki T, Kobayashi Y, Harada K, Amano T, Nakamura M, Kudo M, Tateyama M, Hatanaka K, Saitoh S, Miyagishima T, Kato T, Kawamoto Y, Takagi T, Iwanaga I, Miyashita K, Onodera M, Sakata Y.
The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Including multivariate analysis of two phase II studies.

The 64th Annual Meeting of the AmericanAssociation for the Study of Liver Diseases (AASLD 2013)
2013. 11. Washington DC, USA

<Poster>
Hige S, Karino Y, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Ozeki I, Sato T, Ohmura T, Toyota J.
Paradoxical progression of anemia at delayed phase of triple therapy with telaprevir for ITPA non-CC patients with chronic hepatitis C.
Karino Y, Ozeki I, Hige S, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Sato T, Ohmura T, Toyota J, Chi H, Miki D, Chayama K.
Analysis of the usefulness of HCV core amino acid substitution, serum IP-10 level and IFNL4 genotype as the predictive factor of anti-HCV effect in triple therapy including protease inhibitor.
Karino Y, Ozeki I, Hige S, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Sato T, Ohmura T, Toyota J.
Examination of the optimal dose of RBV in the PEG-IFN/RBV/TVR combination therapy.
Suda G ,Tsukuda Y, Tsunematsu S, Satou F, Terasita K, Horimoto K, Sho T, Nakai M, Natsuizka M, Chuma M, Sakamoto N.
Establishment of Interferon resistant genotype 2b/JFH-1 chimeric HCV cell culture system.

The 1st European Work Shop for Treatment of Head and Neck disease
2013.10. Hamburg, Germany

<Poster>
Shimizu Y, Takahashi M, Yoshida T, Ono S, Mabe K, Kato M, Sakamoto N.
Endoscopic resection fou early stage head and neck cancer.

Euroson
2013.10. Stuttgart, Germany

<Poster>
Sato T, Yamazaki K, Toyota J, Karino Y, Ohmura T.
Diagnosis of gastric varices secondary to splenic vein occlusion by endoscopic color Doppler ultrasonography.

The 22nd Asia Pacific Cancer Conference
2013.11. Tianjin, China

<Oral Presentation>
Ehira N, Yuki S, Iwanaga I, Uebayashi M, Harada K, Kobayashi Y, Sasaki T, Fukushima H, Ishiguro A, Takahata T, Sato A, Dazai M, Sogabe S, Miyagishima T, Takano M, Kudo M, Kato S, Kato K, Sakata Y, Komatsu Y.
An open, multi-center, phase II clinical trial to evaluate efficacy and safety of S-1 plus split Cisplatin in patients with advanced gastric cancer(AGC). - HGCSG0702 : Preliminary report.
<Poster>
Doi A, Sasaki T, Yuki S, Tsuji Y, Hatanaka K, Okuda H, Fujikawa K, Ando T, Iwanaga I, Kato T, Koike M, Watanabe Y, Nakamura M, Miyagishima T, Sato Y, Eto K, Kudo M, Ohta T, Sakata Y, Komatsu Y.
Comparison of cetuximab with panitumumab in salvageline monotherapy against KRAS wild type patients with metastatic colorectal cancer: The integrated analyze of two retrospective trials . HGCSG0901 and HGCSG1002.
Fukushima H, Yuki S, Sasaki T, Note M, Kuno K, Tateyama M, Ishiguro A, Sato A, Akakura N, Munakata M, Hisai H, Ikeda S, Saitoh M, Nakatsumi H, Onodera M, Iwai K, Takagi T, Kato K, Sakata Y, Komatsu Y.
Retrospective comparison of adding cetuximab or panitumumab to irinotecan in salvage-line chemotherapy against KRAS wild type patients with metastatic colorectal cancer: The integrated analyze of two retrospective trials. -HGCSG0901 and HGCSG1002.
Kawamoto Y, Yuki S, Akakura N, Sasaki T, Nakamura M, Shuji N, Hatanaka K, Narues H, Saitoh S, Dazai M, Takuto M, Kato T, Meguro T, Sonoda N, Tateyama M, Takano M, Kudo M, Amano T, Sakata Y, Komatsu Y.
Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC) - Final analysis - : Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.
Nakamura M, Yuki S, Kobayashi Y, Okuda H, Doi A, Tsuji Y, Hatanaka K, Iwanaga I, Koike M, Meguro T, Sogabe S, Ohnuma H, Takahashi Y, Ohta T, Hosokawa A, Hisai H, Yamamoto F, Kudo M, Sakata Y, Komatsu Y.
Retrospective cohort study on the safety and efficacy of Panitumumab (Pmab) for metastatic colorectal cancer (mCRC) patients: HGCSG1002 - Analysis of early clinical predictor for the efficacy -.
Yuki S, Komatsu Y, Fukushima H, Doi A, Tsuji Y, Hatanaka K, Okuda H, Fujikawa K, Watanabe Y, Hosokawa A, Amano T, Eto K, Kudo M, Akakura N, Munakata M, Tateyama M, Sato Y, Miyagishima T, Uebayashi M, Sakata Y.
Analysis of Kohne・スfs prognostic index in KRAS wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.

21th United European Gastroenterology Week (UEGW 2013)
2013.10. Berlin, Germany

<Oral Presentation>
Kato M, Mabe K, Ohno M, Ohmori S, Suzuki M, Takahashi M, Yoshida T, Ono S, Shimizu Y, Sakamoto N.
Investigation about the risk of gastric cancer after successful eradication of H. pylori.
<Poster>
Mabe K, Nakagawa S, Seki H, Katsuki S, Yamashita K, Kato M, Sakamoto N.
A large-scale multicenter prospective study validating the criteria for periendoscopic antithrombotic therapy cessation: the sapporo consensus.
Abe Y, Kawakubo K, Kawakami H, Kuwatani M, Kudo T, Kubo K, Sakamoto N.
Longer length to the stricture from the papilla was risk factor for dysfunction of covered metal stent in patients with distal malignant biliary obstruction.

7th Meeting of the Society of Gastrointestinal Intervention (SGI 2013)
2013.10. Seoul, Korea

<Oral Presentation>
Kawakubo K, Isayama H, Kato H, Japan EUS-BD study group.
A multicenter retrospective study of Endoscopic Ultrasoundguided Biliary Drainage (EUS-BD) for malignant biliary obstruction in Japan.
<Poster>
Haba S, Kawakami H, Kuwatani M, Kawakubo K, Kudo T, Abe Y, Kubo K, Sakamoto N.
Duodenal stricture and the pre-procedural cholangitis are the significant factors for the incidence of complication of endoscopic ultrasound-guided choledochoduodenostomy.
Kuwatani M, Kawakami H, Kudo T, Kawakubo K, Abe Y, Sakamoto N.
Preoperative biliary drainage for malignant hilar biliary stricture caused by gallbladder carcinoma or intrahepatic cholangiocarcinoma.

22nd Asia Pacific Cancer Conference (APCC 2013)
2013.10. Peking, China

<Oral Presentation>
Ehira N, Yuki S, Iwanaga I, Uebayashi M, Harada K, Kobayashi Y, Sasaki T, Fukushima H, Ishigro A, Takahata T, Sato A, Dazai M, Sogabe S, Miyagishima T, Takano M, Kudo M, Kato K, Sakata Y, Komatsu Y.
An open, multicenter, phase II clinical trial to evaluate efficacy and safety of S-1 plus cisplatin in patients with advanced gastric cancer (AGC): HGCSG0702: preliminary report.
<Poster>
Iwanaga I, Ehira N, Ohara M, Sugiura R, Miyamoto S, Mizushima T, Uebayashi M.
Correlation of post-progression survival and the proportion of patients receiving second-line chemotherapy in advanced gastric cancer.
Yuki S, Komatsu Y, Fukushima H, Doi A, Tsuji Y, Hatanaka K, Okuda H, Fujikawa K, Watanabe Y, Hosokawa A, Amano T, Eto K, Kudo M, Akakura N, Munakata M, Tateyama M, Sato Y, Miyagishima T, Uebayashi M, Sakata Y.
Analysis of Kohne・スfs prognostic index in KRAS wild type patients with metastatic colorectal analysis of Kohne's prognostic index in KRAS wild type patients with metastatic colorectal.

European Society for Medical Oncology (ESMO 2013)
2013.9. Amsterdam, Netherland

<Poster>
Hatanaka K, Yuki S, Okuda H, Hosokawa A, Iwanaga I, Sakata Y, Komatsu Y.
Comparison of cetuximab with panitumumab in salvageline monotherapy against KRAS wild type patients with metastatic colorectal cancer.

The 6th International Conference on Colonic Spirochaetal Infections in Animals and Humans
2013.9. Guildford, United Kingdom

<Oral Presentation>
Ono M, Mabe K, Ohnishi S, Omori S, Hatanaka K, Suzuki M, Takahashi M, Ono S, Shimizu Y, Kato M, Sakamoto N.
Histological and molecular examinations of intestinal spirochetosis in patients with sessile serrated adenoma/polyps.

European Cancer Congress (ECC 2013)
2013.9. Amsterdam, Netherland

<Poster>
Dazai M, Fukushima H, Sasaki T, Miyagishima T, Iwanaga I, Kudo M, Hatanaka K, Kato K, Sakata Y, Komatsu Y.
Randomized trial to explore indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV)/acuteonset diarrhea induced by IRIS/FOLFIRI: an exploratory trial .HGCSG0704-.
Fukushima H, Komatsu Y, Yuki S, Sasaki T, Kobayashi Y, Harada K, Kawamoto Y, Nakatsumi H, Dazai M, Sakamoto N.
Serum alpha-fetoprotein (AFP) level is a prognostic factor for advanced gastric cancer.
Hatanaka K, Yuki S, Sasaki T, Tsuji Y, Okuda H, Takahashi Y, Hosokawa A, Iwanaga I, Sakata Y, Komatsu Y.
Comparison of cetuximab with panitumumab in salvageline monotherapy against KRAS wild type patients with metastatic colorectal cancer: Analysis of HGCSG0901 and HGCSG1002.
Ishiguro A, Yuki S, Fukushima H, Sato A, Iwanaga I, Miyagishima T, Kudo M, Kato K, Sakata Y, Komatsu Y.
An open, multi-center, phase II clinical trial to evaluate efficacy and safety of S-1 plus split cisplatin in patients with advanced gastric cancer (AGC) - HGCSG0702 preliminary report.
Komatsu Y, Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Baba H, Tsuji A, Yamaguchi K, Muro K, Ohtsu A.
The relevance of thymidine kinase 1 (TK1) expression to treatment efficacy of TAS-102 and prognosis in patients (pts) with metastatic colorectal cancer (mCRC).
Matsumoto H,Yamada Y, Takahari D, Baba H, Yoshida K, Komatsu Y, Satoh T, Muro K, Shimada Y, Sugihara K.
The SOFT study: A randomized phase III trial of S-1/ oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/ oxaliplatin (mFOLFOX6) plus bevacizmab in patients with metastatic colorectal cancer [SOFT Study Group].
Saitoh S, Yuki S, Harada K, Nakamura M, Hatanaka K, Miyagishima T, Kudo M, Akakura N, Sakata Y, Komatsu Y.
Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/BV) in patients with metastatic colorectal cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) tria l- comparison of the efficacy of KRAS status.
Sasaki K, Okita K, Yuki S, Takahashi Y, Abe M, Hatanaka K, Isobe H, Sogabe S, Oba K, Komatsu Y.
A randomized phase III trial of palonosetron plus dexamethasone (day 1) versus palonosetron plus dexamethasone (day 1-3) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy, not including a combination of anthracycline plus cyclophosphamide.
Yuki S, Komatsu Y, Tsuji Y, Hatanaka K, Okuda H, Fujikawa K, Watanabe Y, Hosokawa A, Amano T, Sakata Y.
Analysis of Kohne's prognostic index in KRAS wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.

International Association of Pancreatology (IAP 2013)
2013.7. Seoul, Korea

<Poster>
Kawakubo K, Kawakami H, Kuwatani M, Kudo T, Abe Y, Kubo K, Sakamoto N.
Recent development of covered metallic stent improved stent patency by using the competing risk regression model.

ASCO annual meeting (ASCO 2013)
2013.6. Chicago, USA

<Poster>
Koeda K, Sugimoto N, Tanaka J, Tsuda M, Okamoto W, Okuda H, Imamura H, Matsuyama J, Shimokawa T, Sakai D, Fukushima N, Kurokawa Y, Komatsu Y, Tsujinaka T, Furukawa H.
A phase ll study of new combination regimen with trastuzumab, S-1, and CDDP in HER2-positive advanced gastric cancer (HERBIS-1).
Nishina T, Fuse N, Kuwata T, Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, Goji T, Yamanaka T, Sasaki T, Shitara K, Kuboki Y, Yoshino T, Ochiai A, Ohtsu A.
Prognostic impact of human epidermal growth factor-2 (HER2) status on overall survival (OS) of advanced gastric cancer (AGC) patients (pts) treated with standard chemotherapy without trastuzumab in the first-line treatment: a Japanese multicenter collaborative retrospective study.
Shichinohe T, Komatsu Y, Akazawa K, Yuki S, Fukushima H, Ohno K, Nakamura F, Kusumi T, Morita T, Senmaru N, Kumagai N, Hirano S.
Randomized phase III clinical study comparing postoperative UFT/LV,UFT+LV/UFT and UFT+LV+PSK/UFT+PSK as adjuvant therapy for curatively resected stage III colorectal cancer HGCSG-CAD study.
Shitara K, Yuki S, Takahari D, Nakamura M, Kondo C, Tsuda T, Kii T, Tsuji Y, Utsunomiya S, Ichikawa D, Hosokawa A, Ishiguro A, Sakai D, Hironaka S, Matsuo K, Oze I, Muro K.
Randomized phase II study comparing dose-escalated weekly paclitaxel (wPTX) versus standard-dose wPTX for patients with previously treated advanced gastric cancer (AGC).
<Panel Discussion>
Takahari D, Yamada Y, Matsumoto H, Baba H, Yoshida K, Nakamura M, Yoshida M, Iwamoto S, Takinishi Y, Sakata Y, Morita S, Shimada Y, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sugihara K.
A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizmab in patients with metastatic colorectal cancer: The SOFT study.

ASLD/EASL Clinical Research Single Topic Conference, Portal Hyertension and Variceal Hemorrhage
2013.6. Atlanta, USA

<Poster>
Sato T, Yamazaki K, Kimura M.
Treatment for rectal variceal bleeding with portal hypertension.

23rd Conference of the Asia Pacific Association for the Study of the Liver (APASL 2013)
2013.6. Singapore

<Oral Presentation>
Karino Y, Toyota J, Lataillade M, Izumi N, Chayama K, Mochida S, Kawada N, Ishikawa H, Hosokawa E, Imai J, Scricca R, Cohen D, Xu D, Horga M, Yogaratnam J, Srinivasan S, Kumada H and Lopez-Talavera J-C for the D-LITE study team.
Peginterferon lambda-1a/Ribavirin with daclatasvir or asunaprevir in HCV genotype 1b: Sustained virologic response (SVR12) in the D-LITE Japanese sub-study.

International Society for Stem Cell Research 2013 (ISSCR2013)
2013.6. Boston, USA

<Poster>
Ohnishi S, Onishi R, Higashi R, Yamahara K, Watari M, Kobayashi W, Katsurada T, Takeda H, Sakamoto N.
Transplantation of human amnion-derived mesenchymal stem cells improves severe colitis via attenuation of macrophage activity in rats.

The 10th International Gastric Cancer Congress (IGCC 2013)
2013.6. Verona, Italy

<Oral Presentation>
Sogabe S, Fukushima H, Yuki S, Miyagishima T, Ishiguro A, Takahata T, Kudo M, Uehata Y, Iwanaga I, Sakata Y, Komatsu Y.
An open, multi-center, phase II clinical trial to evaluate efficacy and safety of S-1 plus split Cisplatin(SSP) in patients with advanced gastric cancer(AGC). - HGCSG0702 : Preliminary analysis.
Tsuda M, Sugimoto N, Tanaka J, Okamoto W, Miwa H, Nishina S, Okuda H, Imamura H, Matsuyama J, Shimokawa T, Sakai D, Gamoh M, Kurokawa Y, Komatsu Y, Tsujinaka T, Furukawa H.
A phase II study of trstuzumab in combination with triweekly S-1 plus CDDP in HER2-positiveadvanced gastric cancer; OGSG1101,HGCSG1102, T-CORE1101 Intergroup study (HERBIS-1 trial).
<Poster>
Fukushima H, Yuki S, Kobayashi Y, Sasaki T, Dazai M, Komatsu Y, Sakamoto N.
Serum Alpha-fetoprotein (AFP) level is a prognostic factor for advanced gastric cancer?
Kato ・スl, Mabe K, Ohno M, Ohmori S, Suzuki M, Takahashi M, Ono S, Shimizu Y, Sakamoto N, Asaka M.
National survey about the incidence of gastric cancer after successful eradication of H. pylori.
Ono S, Kato M, Mabe K, Ono M, Suzuki M, Omori S, Takahashi M, Shimizu Y, Sakamoto N.
Preliminary reports of prospective gatric ESD training for novice operators.
Suzuki M, Kato M, Ono S, Sakamoto N.
Postoperative hemorrhage after gastric ESD in patients receiving 'bridging therapy' with heparin - multicenter survey in Japan -.

International Digestive Endoscopy Network (IDEN 2013)
2013.6. Seoul, Korea

<Oral Presentation>
Kawakubo K, Kawakami H, Kuwatani M, Kudo T, Abe Y, Sakamoto N.
Risk for technical failure of endoscopic multiple metallic stent placement by stent-in-stent method for unresectable malignant hilar biliary obstruction.

Tokyo Conference of Asian Pancreato-Biliary Interventional Endoscopist (T-CAP 2013)
2013.6. Tokyo, Japan

<Oral Presentation>
Kuwatani M, Kawakami H, Kudo T, Kawakubo K, Abe Y, Sakamoto N.
The efficacy of high negative pressure suction in EUS-FNA of the pancreatic mass.
<Poster>
Kawakubo K, Kawakami H, Kuwatani M, Kudo T, Abe Y, Sakamoto N.
Risk for technical failure of endoscopic multiple metallic stent placement by stent-in-stent method for unresectable malignant hilar biliary obstruction.

Digestive Dlsease Week (DDW 2013)
2013.5. Orland, USA

<Oral Presentation>
Kato M, Takeda H, Tominaga K, Shimoyama Y, Umegaki E, Iwakiri R, Furuta K, Sakurai K, Odaka T, Kusunoki H, Nagahara A, Iwakiri K, Furuta T, Murakami K, Miwa H, Kinoshita Y, Haruma K, Takahashi S, Watanabe S, Higuchi K, Kusano M, Fujimoto K, Arakawa T, and the G-PRIDE study group.
A randomized, controlled, double-blind clinical trial of rikkunshito versus placebo for gastrointestinal symptoms and quality of life in patients with proton pump inhibitor -refractory non-erosive reflux disease: the G-PRIDE study.
<Poster>
Kawakami H, Kuwatani M, Kawakubo K, Haba S, Kudo T, Abe Y, Sakamoto N.
A novel endoscopic approach to severe strictures of the biliary or main pancreatic duct using a diathermic sheath.
Kawakubo K, Kawakami H, Kuwatani M, Haba S, Kudo T, Abe Y, Kubo K, Sakamoto N.
Endoscopic nasobiliary drainage (ENBD) - complications and long term outcomes -.
Kawakubo K, Kawakami H, Kuwatani M, Haba S, Kudo T, Abe Y, Kubo K, Sakamoto N.
A newly designed large cell stent for endoscopic bilateral stent-in-stent placement in patients with malignant hilarbiliary obstruction.
Kuwatani M, Kawakami H,Kawakubo K , Haba S, Kudo T, Abe Y, Sakamoto N.
Efficacy of antispasmodic drugs for endoscopic ultrasonography. interim analysis of a multicenter prospective randomized controlled trial.
Ohnishi S, Muto S, Nakagawa K, Sadakane C, Saegusa Y, Nahata M, Yamada C, Hattori T, Asaka M, Sakamoto N, Takeda H.
Involvement of ghrelin signaling dysfunction in acute restraint stress-induced delayed gastric emptying.
Onishi R, Ohnishi S, Higashi R, Watari M, Kobayashi W, Katsurada T, Takeda H, Sakamoto N.
Transplantation of human fetal membrane-derived mesenchymal stem cells improves severe colitis induced by dextran sulfate sodium in rats.
Takahashi M, Shimizu Y, Ono S, Mabe K, Kato M, Sakamoto N.
Endoscopic diagnosis of intraepithelial squamous neoplasia of the esophagus with narrow band imaging: Comparison of intervascular background coloration, iodine staining findings and histological findings.
Yoshii S, Nojima M, Nosho K, Omori S, Kusumi T, Okuda H, Tsukagoshi H, Fujita M, Yamamoto H, Hosokawa M.
The long-term efficacy of subsequent surgery for T1 colorectal cancer after endoscopic resection: A cohort study with propensity-score adjustment.

48th Annual Meeting of the European Association of the Study of the Liver (EASL 2013)
2013. 4. Amsterdam, Netherland

<Poster>
Chuma M, Sakamoto N, Hige S, Nakanishi M, Natsuizaka M,Suda G, Sho T, Maeda S.
Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor・ス・スB/mitogenactivated protein kinase.
Karino Y, Ozeki I, Hige S, Kimura M, Arakawa T, Nakajima T,Kuwata Y, Sato T, Ohmura T, Toyota J.
Rbv blood concentration at first week of peg-ifn/rbv/tvr combination therapy is a good predictive marker of renal dysfunction and anemia.
Karino Y, Ozeki I, Hige S, Toyota J, Imamura M, Tsume M, Chayama K, Akuta N, Suzuki F, Kumada H.
Analysis of the optimal tvr dose per weight judging from anemia during peg-ifn/rbv/tvr combination therapy.

Bonastent Summit 2013.
2013.4. Busan, Korea

<Oral Presentation>
Kawakami H.
Stenting for malignant hilar biliary stricture-resectable hilarcholangiocarcinoma-

>